AU2008335840A1 - Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic T lymphocyte-associated antigen 4 (CTLA4) - Google Patents

Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic T lymphocyte-associated antigen 4 (CTLA4) Download PDF

Info

Publication number
AU2008335840A1
AU2008335840A1 AU2008335840A AU2008335840A AU2008335840A1 AU 2008335840 A1 AU2008335840 A1 AU 2008335840A1 AU 2008335840 A AU2008335840 A AU 2008335840A AU 2008335840 A AU2008335840 A AU 2008335840A AU 2008335840 A1 AU2008335840 A1 AU 2008335840A1
Authority
AU
Australia
Prior art keywords
day
dosage
days
melanoma
ctla4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008335840A
Other languages
English (en)
Inventor
Israel Rios
Cynthia W. Tuthill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sciclone Pharmaceuticals LLC
Original Assignee
Sciclone Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals LLC filed Critical Sciclone Pharmaceuticals LLC
Publication of AU2008335840A1 publication Critical patent/AU2008335840A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2008335840A 2007-12-12 2008-12-08 Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic T lymphocyte-associated antigen 4 (CTLA4) Abandoned AU2008335840A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1310107P 2007-12-12 2007-12-12
US61/013,101 2007-12-12
PCT/US2008/013480 WO2009075813A1 (en) 2007-12-12 2008-12-08 Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4)

Publications (1)

Publication Number Publication Date
AU2008335840A1 true AU2008335840A1 (en) 2009-06-18

Family

ID=40755783

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008335840A Abandoned AU2008335840A1 (en) 2007-12-12 2008-12-08 Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic T lymphocyte-associated antigen 4 (CTLA4)

Country Status (8)

Country Link
US (1) US20100330093A1 (enExample)
EP (1) EP2240195A4 (enExample)
JP (1) JP2011506436A (enExample)
CN (1) CN101896190A (enExample)
AR (1) AR069682A1 (enExample)
AU (1) AU2008335840A1 (enExample)
CA (1) CA2709027A1 (enExample)
WO (1) WO2009075813A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130296223A1 (en) * 2012-03-30 2013-11-07 Sciclone Pharmaceuticals, Inc. Use of thymosin alpha for the treatment of sepsis
WO2013177102A2 (en) * 2012-05-21 2013-11-28 Felder Mitchell S Treatment of cancer by manipulating the immune system
EP3943101A1 (en) 2014-10-21 2022-01-26 SciClone Pharmaceuticals International Ltd. Treatment of cancer with immune stimulator alpha thymosin peptide
US10806787B2 (en) 2015-02-16 2020-10-20 Pharma Foods International Co., Ltd. Anticancer agents or antimetastatic agents using FSTL1 and combination drug thereof
JP7069032B2 (ja) 2016-03-24 2022-05-17 ミレニアム ファーマシューティカルズ， インコーポレイテッド がん免疫治療における胃腸の免疫関連有害事象の治療方法
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
CN109793891A (zh) * 2017-11-17 2019-05-24 韩震 多肽化合物在制备提高治疗性抗体疗效的佐剂中的应用与组合物及其制备方法
IT201900016310A1 (it) * 2019-09-13 2021-03-13 Luigina Romani Timosina alfa 1 per l’uso nella prevenzione e nel trattamento degli effetti avversi immunitari correlati agli inibitori di checkpoint immunitari.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2604845A1 (de) * 1976-02-07 1977-08-18 Knoll Ag Neue piperazinderivate
EP2633866A3 (en) * 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy

Also Published As

Publication number Publication date
US20100330093A1 (en) 2010-12-30
CA2709027A1 (en) 2009-06-18
WO2009075813A1 (en) 2009-06-18
EP2240195A1 (en) 2010-10-20
CN101896190A (zh) 2010-11-24
EP2240195A4 (en) 2011-12-21
AR069682A1 (es) 2010-02-10
JP2011506436A (ja) 2011-03-03

Similar Documents

Publication Publication Date Title
JP2023524530A (ja) 免疫原性が低い癌の癌細胞死滅を増強するための３剤併用療法
US20100330093A1 (en) Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4)
EP3065765B1 (en) Use of il-22 dimers in manufacture of medicaments for treating pancreatitis
US7851443B2 (en) Combination comprising combretastatin and anticancer agents
US20100221274A1 (en) Method of administering a thymosin alpha 1 peptide
EP3042669A1 (en) Antitumor agent and antitumor effect enhancer
US20050112061A1 (en) Use of a VEGF antagonist in combination with radiation therapy
US20050196340A1 (en) Use of a VEGF antagonist in combination with radiation therapy
WO2009079338A1 (en) Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (hsaa)
CN111836647A (zh) Cd47阻断疗法和cd38抗体的组合
JP6782932B2 (ja) Ｎｐｒ−ａアゴニストの新規用途
US20210130403A1 (en) Inhibitors of metastasis
US9486503B2 (en) Medicinal agent for suppressing malignant tumor metastasis
RU2639445C2 (ru) Лекарственное средство, содержащее рекомбинантные лектины омелы, для лечения злокачественной меланомы
WO2016071431A1 (en) A combination for cancer therapy
US11497793B2 (en) Compositions and methods for treating glioblastoma
TW202322855A (zh) 人類表皮生長因子第二型受體疫苗組成物以及套組
US20100267637A1 (en) Treatment of melanoma with alpha thymosin peptides in combination with a kinase inhibitor
WO2025032571A1 (en) Unit dosage forms and methods comprising bl8040 for intravenous administration
CN117281902A (zh) 一种药物组合物在制备治疗黑色素瘤产品中的应用
WO2011054894A1 (en) Composition for treating insulin resistance

Legal Events

Date Code Title Description
MK3 Application lapsed section 142(2)(c) - examination deferred under section 46 no request for examination